Literature DB >> 30379691

Successful use of the potent enzyme inducer enzalutamide in a treatment-experienced HIV-positive male with prostate cancer.

Salin Nhean1,2, Jam Bravo1, Nancy L Sheehan2,3, Sharon Walmsley1,4, David Tilley5, Alice L Tseng1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30379691     DOI： 10.1097/QAD.0000000000002019

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  2 in total

1.  Re: Silke Gillessen Sommer, Thomas Powles. Advice for Medical Oncology Care of Urological Cancer Patients During the COVID-19 Pandemic. Eur Urol 2020;78:e2-3: Is It Always Correct to Continue Androgen Receptor Signaling Inhibitors in the COVID-19 Era?

Authors:  Giuseppe Di Lorenzo
Journal:  Eur Urol       Date:  2020-04-24       Impact factor: 20.096

Review 2.  The Deadly Duo of COVID-19 and Cancer!

Authors:  Vivek R Bora; Bhoomika M Patel
Journal:  Front Mol Biosci       Date:  2021-04-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.